New updates in COVID-19 research: Emerging therapeutic role of Fexofenadine and Montelukast.
The dawn of the year 2020 witnessed the surge of one of the biggest pandemics known to mankind. COVID-19 spread through continents affecting millions of humans and causing great damage to life and property.
With the lack of effective antiviral therapy, immediate repurposing of existing drugs is a ray of hope in curbing this pandemic. In this regard, recent research shows that two commonly used drugs for seasonal allergic rhinitis (SAR) and asthma –fexofenadine and montelukast- can be repurposed for use in COVID-19.(1) These two drug classes have been shown to possess direct viral protein binding properties besides combatting the cytokine storm through inhibition of histamine and interleukin-6 (IL-6) release. (2, 3)